These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
235 related items for PubMed ID: 9354587
21. Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition. Wilson CR, Sauer JM, Carlson GP, Wallin R, Ward MP, Hooser SB. Toxicology; 2003 Aug 01; 189(3):191-8. PubMed ID: 12832152 [Abstract] [Full Text] [Related]
22. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Wallin R, Sane DC, Hutson SM. Thromb Res; 2002 Nov 25; 108(4):221-6. PubMed ID: 12617985 [Abstract] [Full Text] [Related]
23. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes. Fasco MJ, Principe LM, Walsh WA, Friedman PA. Biochemistry; 1983 Nov 22; 22(24):5655-60. PubMed ID: 6652076 [Abstract] [Full Text] [Related]
24. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. Nature; 2022 Aug 22; 608(7924):778-783. PubMed ID: 35922516 [Abstract] [Full Text] [Related]
26. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle. Guenthner TM, Cai D, Wallin R. Biochem Pharmacol; 1998 Jan 15; 55(2):169-75. PubMed ID: 9448739 [Abstract] [Full Text] [Related]
30. Reduced thioredoxin: a possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide. Silverman RB, Nandi DL. Biochem Biophys Res Commun; 1988 Sep 30; 155(3):1248-54. PubMed ID: 3140805 [Abstract] [Full Text] [Related]
31. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. Thijssen HH, Baars LG, Vervoort-Peters HT. Br J Pharmacol; 1988 Nov 30; 95(3):675-82. PubMed ID: 3207986 [Abstract] [Full Text] [Related]
32. Vitamin K metabolism and vitamin K1 status in human liver samples: a search for inter-individual differences in warfarin sensitivity. Thijssen HH, Drittij-Reijnders MJ. Br J Haematol; 1993 Aug 30; 84(4):681-5. PubMed ID: 8217828 [Abstract] [Full Text] [Related]
33. Vitamin K epoxide reductase activity in the metabolism of epoxides. Liptay-Reuter I, Dose K, Guenthner T, Wörner W, Oesch F. Biochem Pharmacol; 1985 Aug 01; 34(15):2617-20. PubMed ID: 4015704 [Abstract] [Full Text] [Related]
34. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes. Hildebrandt EF, Preusch PC, Patterson JL, Suttie JW. Arch Biochem Biophys; 1984 Feb 01; 228(2):480-92. PubMed ID: 6696443 [Abstract] [Full Text] [Related]
35. Inhibition of protein carbonyl formation and lipid peroxidation by glutathione in rat liver microsomes. Palamanda JR, Kehrer JP. Arch Biochem Biophys; 1992 Feb 14; 293(1):103-9. PubMed ID: 1731626 [Abstract] [Full Text] [Related]
36. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver. Begent LA, Hill AP, Steventon GB, Hutt AJ, Pallister CJ, Cowell DC. J Pharm Pharmacol; 2001 Apr 14; 53(4):481-6. PubMed ID: 11341364 [Abstract] [Full Text] [Related]